CIK 0001442836
MRSN Mersana Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Sep 15, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Mersana Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Martin H. Huber Jr. President, CEO sell | $15k 2,012 shares | -17% | - | |
| 0Weak | Mohan Bala SVP, Chief Development Officer sell | $3,445 5,939 shares | -8% | - | |
| 0Weak | Alejandra Carvajal SVP, Chief Legal Officer sell | $2,956 5,096 shares | -6% | - | |
| 2Weak | Brian DeSchuytner SVP, COO & CFO sell | $4,913 8,470 shares | -7% | - | |
| 5Weak | Martin H. Huber Jr. President, CEO sell | $2,618 4,514 shares | -4% | - | |
| 0Weak | Alejandra Carvajal SVP, Chief Legal Officer sell | $600 952 shares | -1% | - | |
| 2Weak | Brian DeSchuytner SVP, COO & CFO sell | $1,469 2,331 shares | -2% | - | |
| 0Weak | Mohan Bala SVP, Chief Development Officer sell | $2,147 3,253 shares | -5% | - | |
| 0Weak | Alejandra Carvajal SVP, Chief Legal Officer sell | $2,198 3,330 shares | -5% | - | |
| 2Weak | Brian DeSchuytner SVP, COO & CFO sell | $2,451 3,713 shares | -3% | - | |
| 0Weak | Mohan Bala SVP, Chief Development Officer sell | $3,580 1,884 shares | -3% | - |
Transactions
The last 53 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | Martin H. Huber Jr. President, CEO | MOption exercise Common Stock10b5-1 | +6,670 | $0.00 | $0 | 11,584 | Sep 15, 2025 |
| Sep 12, 2025 | Martin H. Huber Jr. President, CEO | SOpen-market sale Common Stock10b5-1 | -2,012 | $7.31 | $15k | 9,572 | Sep 15, 2025 |
| Sep 11, 2025 | Martin H. Huber Jr. President, CEO | MOption exercise Restricted Stock Unitderivative10b5-1 | -6,670 | $0.00 | $0 | 13,340 | Sep 15, 2025 |
| Jun 12, 2025 | Lawrence M Alleva director | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jun 12, 2025 | Willard H Dere director | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jun 12, 2025 | Allene M. Diaz director | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jun 12, 2025 | Andrew A. F. Hack director | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jun 12, 2025 | Kristen Hege director | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jun 12, 2025 | David M Mott director | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jun 12, 2025 | Anna Protopapas director | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jan 15, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Common Stock10b5-1 | +6,250 | $0.00 | $0 | 115,280 | Jan 17, 2025 |
| Jan 15, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | MOption exercise Common Stock10b5-1 | +12,500 | $0.00 | $0 | 83,392 | Jan 17, 2025 |
| Jan 15, 2025 | Martin H. Huber Jr. President, CEO | MOption exercise Common Stock10b5-1 | +11,062 | $0.00 | $0 | 127,389 | Jan 17, 2025 |
| Jan 15, 2025 | Mohan Bala SVP, Chief Development Officer | MOption exercise Common Stock10b5-1 | +14,583 | $0.00 | $0 | 74,811 | Jan 17, 2025 |
| Jan 16, 2025 | Martin H. Huber Jr. President, CEO | SOpen-market sale Common Stock10b5-1 | -4,514 | $0.58 | $2,618 | 122,875 | Jan 17, 2025 |
| Jan 16, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -5,096 | $0.58 | $2,956 | 78,296 | Jan 17, 2025 |
| Jan 16, 2025 | Mohan Bala SVP, Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -5,939 | $0.58 | $3,445 | 68,872 | Jan 17, 2025 |
| Jan 15, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Common Stock10b5-1 | +14,583 | $0.00 | $0 | 129,863 | Jan 17, 2025 |
| Jan 15, 2025 | Mohan Bala SVP, Chief Development Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -14,583 | $0.00 | $0 | 43,750 | Jan 17, 2025 |
| Jan 15, 2025 | Martin H. Huber Jr. President, CEO | MOption exercise Restricted Stock Unitderivative10b5-1 | -11,062 | $0.00 | $0 | 33,188 | Jan 17, 2025 |
| Jan 16, 2025 | Brian DeSchuytner SVP, COO & CFO | SOpen-market sale Common Stock10b5-1 | -8,470 | $0.58 | $4,913 | 121,393 | Jan 17, 2025 |
| Jan 15, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -12,500 | $0.00 | $0 | 37,500 | Jan 17, 2025 |
| Jan 15, 2025 | Martin H. Huber Jr. President, CEO | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +816,300 | $0.00 | $0 | 816,300 | Jan 17, 2025 |
| Jan 15, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Restricted Stock Unitderivative10b5-1 | -6,250 | $0.00 | $0 | 0 | Jan 17, 2025 |
| Jan 15, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +243,750 | $0.00 | $0 | 243,750 | Jan 17, 2025 |
| Jan 15, 2025 | Mohan Bala SVP, Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +281,250 | $0.00 | $0 | 281,250 | Jan 17, 2025 |
| Jan 15, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | AGrant or award Restricted Stock Unitderivative10b5-1 | +54,167 | $0.00 | $0 | 54,167 | Jan 17, 2025 |
| Jan 15, 2025 | Martin H. Huber Jr. President, CEO | AGrant or award Restricted Stock Unitderivative10b5-1 | +181,400 | $0.00 | $0 | 181,400 | Jan 17, 2025 |
| Jan 15, 2025 | Mohan Bala SVP, Chief Development Officer | AGrant or award Restricted Stock Unitderivative10b5-1 | +62,500 | $0.00 | $0 | 62,500 | Jan 17, 2025 |
| Jan 15, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Restricted Stock Unitderivative10b5-1 | -14,583 | $0.00 | $0 | 43,750 | Jan 17, 2025 |
| Jan 15, 2025 | Brian DeSchuytner SVP, COO & CFO | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +281,250 | $0.00 | $0 | 281,250 | Jan 17, 2025 |
| Jan 15, 2025 | Brian DeSchuytner SVP, COO & CFO | AGrant or award Restricted Stock Unitderivative10b5-1 | +62,500 | $0.00 | $0 | 62,500 | Jan 17, 2025 |
| Jan 14, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | MOption exercise Common Stock10b5-1 | +2,500 | $0.00 | $0 | 71,844 | Jan 16, 2025 |
| Jan 14, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Common Stock10b5-1 | +6,250 | $0.00 | $0 | 111,361 | Jan 16, 2025 |
| Jan 15, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -952 | $0.63 | $600 | 70,892 | Jan 16, 2025 |
| Jan 15, 2025 | Brian DeSchuytner SVP, COO & CFO | SOpen-market sale Common Stock10b5-1 | -2,331 | $0.63 | $1,469 | 109,030 | Jan 16, 2025 |
| Jan 14, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -2,500 | $0.00 | $0 | 2,500 | Jan 16, 2025 |
| Jan 14, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Restricted Stock Unitderivative10b5-1 | -6,250 | $0.00 | $0 | 6,250 | Jan 16, 2025 |
| Jan 13, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Common Stock10b5-1 | +10,000 | $0.00 | $0 | 108,824 | Jan 15, 2025 |
| Jan 13, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | MOption exercise Common Stock10b5-1 | +8,958 | $0.00 | $0 | 72,674 | Jan 15, 2025 |
| Jan 13, 2025 | Mohan Bala SVP, Chief Development Officer | MOption exercise Common Stock10b5-1 | +8,750 | $0.00 | $0 | 63,481 | Jan 15, 2025 |
| Jan 14, 2025 | Brian DeSchuytner SVP, COO & CFO | SOpen-market sale Common Stock10b5-1 | -3,713 | $0.66 | $2,451 | 105,111 | Jan 15, 2025 |
| Jan 14, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -3,330 | $0.66 | $2,198 | 69,344 | Jan 15, 2025 |
| Jan 14, 2025 | Mohan Bala SVP, Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -3,253 | $0.66 | $2,147 | 60,228 | Jan 15, 2025 |
| Jan 13, 2025 | Mohan Bala SVP, Chief Development Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -8,750 | $0.00 | $0 | 17,500 | Jan 15, 2025 |
| Jan 13, 2025 | Alejandra Carvajal SVP, Chief Legal Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -8,958 | $0.00 | $0 | 17,917 | Jan 15, 2025 |
| Jan 13, 2025 | Brian DeSchuytner SVP, COO & CFO | MOption exercise Restricted Stock Unitderivative10b5-1 | -10,000 | $0.00 | $0 | 20,000 | Jan 15, 2025 |
| Jan 2, 2025 | Lawrence M Alleva director | AGrant or award Stock Option (right to buy)derivative | +12,521 | $0.00 | $0 | 12,521 | Jan 3, 2025 |
| Dec 19, 2024 | EcoR1 Capital, LLC owner | JOther Common Stockindirect: See Note | -8,036,688 | - | - | 11,328,000 | Dec 23, 2024 |
| Dec 19, 2024 | EcoR1 Capital, LLC owner | JOther Pre-Funded Warrantsderivativeindirect: See Note | +8,036,688 | - | - | 8,036,688 | Dec 23, 2024 |
| Oct 25, 2024 | Mohan Bala SVP, Chief Development Officer | MOption exercise Common Stock10b5-1 | +6,250 | $0.00 | $0 | 56,615 | Oct 29, 2024 |
| Oct 28, 2024 | Mohan Bala SVP, Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -1,884 | $1.90 | $3,580 | 54,731 | Oct 29, 2024 |
| Oct 25, 2024 | Mohan Bala SVP, Chief Development Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -6,250 | $0.00 | $0 | 6,250 | Oct 29, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Lawrence M Allevadirector
- Mohan BalaSVP, Chief Development Officer
- Alejandra CarvajalSVP, Chief Legal Officer
- Brian DeSchuytnerSVP, COO & CFO
- Willard H Deredirector
- Allene M. Diazdirector
- EcoR1 Capital, LLCowner, director
- Andrew A. F. Hackdirector
- Kristen Hegedirector
- Martin H. Huber Jr.President, CEO
- David M Mottdirector
- Anna Protopapasdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.